Prates-Rodrigues M, Schweizer B, de Paula Gomes C, Ribeiro A, Padovan-Neto F, Masini D
J Neurochem. 2025; 169(2):e70008.
PMID: 39901598
PMC: 11791392.
DOI: 10.1111/jnc.70008.
Linen S, Chang N, Hess E, Stanley G, Waiblinger C
bioRxiv. 2024; .
PMID: 38895263
PMC: 11185599.
DOI: 10.1101/2024.06.05.597339.
Cardoso V, Valente-Amaral A, Monteiro R, Meira C, de Meira N, Da Silva M
Front Neurosci. 2024; 18:1351718.
PMID: 38449740
PMC: 10914943.
DOI: 10.3389/fnins.2024.1351718.
Cui J, Zhao D, Xu M, Li Z, Qian J, Song N
Sci Rep. 2024; 14(1):3721.
PMID: 38355892
PMC: 10866897.
DOI: 10.1038/s41598-024-54066-0.
Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta Iii M, Levesque M
Transl Neurodegener. 2023; 12(1):36.
PMID: 37468944
PMC: 10354932.
DOI: 10.1186/s40035-023-00368-8.
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders.
Ishiguro H, Kibret B, Horiuchi Y, Onaivi E
Front Psychiatry. 2022; 13:828895.
PMID: 35774086
PMC: 9237241.
DOI: 10.3389/fpsyt.2022.828895.
Application of Neurotoxin-Induced Animal Models in the Study of Parkinson's Disease-Related Depression: Profile and Proposal.
Mou Y, Guan L, Yao X, Wang J, Song X, Ji Y
Front Aging Neurosci. 2022; 14:890512.
PMID: 35645772
PMC: 9136050.
DOI: 10.3389/fnagi.2022.890512.
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.
Kibret B, Ishiguro H, Horiuchi Y, Onaivi E
Int J Mol Sci. 2022; 23(2).
PMID: 35055161
PMC: 8778243.
DOI: 10.3390/ijms23020975.
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Antipova V, Holzmann C, Hawlitschka A, Witt M, Wree A
Toxins (Basel). 2021; 13(7).
PMID: 34357977
PMC: 8310221.
DOI: 10.3390/toxins13070505.
Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.
El-Gamal M, Salama M, Collins-Praino L, Baetu I, Fathalla A, Soliman A
Neurotox Res. 2021; 39(3):897-923.
PMID: 33765237
DOI: 10.1007/s12640-021-00356-8.
Role of Liver Growth Factor (LGF) in Parkinson's Disease: Molecular Insights and Therapeutic Opportunities.
Angelopoulou E, Paudel Y, Piperi C
Mol Neurobiol. 2021; 58(7):3031-3042.
PMID: 33608826
DOI: 10.1007/s12035-021-02326-9.
Chemically Induced Models of Parkinson's Disease: History and Perspectives for the Involvement of Ferroptosis.
Wen S, Aki T, Unuma K, Uemura K
Front Cell Neurosci. 2021; 14:581191.
PMID: 33424553
PMC: 7786020.
DOI: 10.3389/fncel.2020.581191.
Probiotics Treatment Improves Hippocampal Dependent Cognition in a Rodent Model of Parkinson's Disease.
Xie C, Prasad A
Microorganisms. 2020; 8(11).
PMID: 33120961
PMC: 7692862.
DOI: 10.3390/microorganisms8111661.
Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?.
Dujardin K, Sgambato V
Front Neurosci. 2020; 14:25.
PMID: 32063833
PMC: 7000525.
DOI: 10.3389/fnins.2020.00025.
Biomolecular Changes and Cortical Neurodegenerative Lesions in Infected BALB/c Mice: A Preliminary Study Elucidating a Potential Relationship Between Systemic Helminthic Infections and Idiopathic Parkinson's.
Hasby Saad M, Safwat O, El-Guindy D, Raafat R, Elgendy D, Hasby E
Helminthologia. 2019; 55(4):261-274.
PMID: 31662657
PMC: 6662001.
DOI: 10.2478/helm-2018-0029.
Investigation of Behavioral Dysfunctions Induced by Monoamine Depletions in a Mouse Model of Parkinson's Disease.
Li Y, Jiao Q, Du X, Bi M, Han S, Jiao L
Front Cell Neurosci. 2018; 12:241.
PMID: 30135645
PMC: 6092512.
DOI: 10.3389/fncel.2018.00241.
Endocannabinoid system in neurodegenerative disorders.
Basavarajappa B, Shivakumar M, Joshi V, Subbanna S
J Neurochem. 2017; 142(5):624-648.
PMID: 28608560
PMC: 5669051.
DOI: 10.1111/jnc.14098.
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.
Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S
Front Neurosci. 2017; 11:30.
PMID: 28210207
PMC: 5288380.
DOI: 10.3389/fnins.2017.00030.
Disrupted brain metabolic connectivity in a 6-OHDA-induced mouse model of Parkinson's disease examined using persistent homology-based analysis.
Im H, Hahm J, Kang H, Choi H, Lee H, Hwang D
Sci Rep. 2016; 6:33875.
PMID: 27650055
PMC: 5030651.
DOI: 10.1038/srep33875.
What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?.
Magnard R, Vachez Y, Carcenac C, Krack P, David O, Savasta M
Transl Psychiatry. 2016; 6:e753.
PMID: 26954980
PMC: 4872443.
DOI: 10.1038/tp.2016.17.